- Home
- VYNE vs LSB Comparison
VYNE vs LSB Comparison
Compare VYNE & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- LSB
- Stock Information
- Founded
- VYNE 2003
- LSB 2002
- Country
- VYNE United States
- LSB China
- Employees
- VYNE N/A
- LSB N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- LSB
- Sector
- VYNE Health Care
- LSB
- Exchange
- VYNE Nasdaq
- LSB NYSE
- Market Cap
- VYNE 35.7M
- LSB 31.5M
- IPO Year
- VYNE 2018
- LSB N/A
- Fundamental
- Price
- VYNE $1.33
- LSB $1.17
- Analyst Decision
- VYNE Strong Buy
- LSB
- Analyst Count
- VYNE 2
- LSB 0
- Target Price
- VYNE $6.25
- LSB N/A
- AVG Volume (30 Days)
- VYNE 223.6K
- LSB 20.7K
- Earning Date
- VYNE 05-08-2025
- LSB 06-21-2025
- Dividend Yield
- VYNE N/A
- LSB N/A
- EPS Growth
- VYNE N/A
- LSB N/A
- EPS
- VYNE N/A
- LSB N/A
- Revenue
- VYNE $605,000.00
- LSB $79,415,311.00
- Revenue This Year
- VYNE N/A
- LSB $39.33
- Revenue Next Year
- VYNE N/A
- LSB $75.61
- P/E Ratio
- VYNE N/A
- LSB N/A
- Revenue Growth
- VYNE 18.16
- LSB N/A
- 52 Week Low
- VYNE $1.27
- LSB $1.15
- 52 Week High
- VYNE $4.30
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- VYNE 33.79
- LSB 29.82
- Support Level
- VYNE $1.27
- LSB $1.16
- Resistance Level
- VYNE $1.41
- LSB $1.28
- Average True Range (ATR)
- VYNE 0.11
- LSB 0.10
- MACD
- VYNE -0.02
- LSB 0.01
- Stochastic Oscillator
- VYNE 0.00
- LSB 5.88
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.